BMO Capital Markets Upgrades Integra LifeSciences (NASDAQ:IART) to “Hold”

Integra LifeSciences (NASDAQ:IART) was upgraded by research analysts at BMO Capital Markets to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also issued reports on IART. Wells Fargo & Company lifted their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Thursday, June 18th. Citigroup reaffirmed a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday. Truist Financial cut their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. Finally, Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $17.17.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $18.39 on Wednesday. The stock’s 50-day simple moving average is $16.15 and its two-hundred day simple moving average is $12.81. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $18.92. The firm has a market capitalization of $1.43 billion, a P/E ratio of -2.85, a P/E/G ratio of 1.20 and a beta of 1.22. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. During the same quarter last year, the company posted $0.41 EPS. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Several hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Integra LifeSciences by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after buying an additional 1,975 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Integra LifeSciences during the 1st quarter valued at about $277,000. Goldman Sachs Group Inc. boosted its holdings in Integra LifeSciences by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after acquiring an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Integra LifeSciences by 23.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after acquiring an additional 45,693 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Integra LifeSciences during the 2nd quarter worth approximately $491,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.